{"id":885145,"date":"2025-09-10T09:33:03","date_gmt":"2025-09-10T13:33:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\/"},"modified":"2025-09-10T09:33:03","modified_gmt":"2025-09-10T13:33:03","slug":"euda-signs-letter-of-intent-to-potentially-acquire-go-posb","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\/","title":{"rendered":"EUDA Signs Letter of Intent to Potentially Acquire GO POSB"},"content":{"rendered":"
\n

\n SINGAPORE, Sept. 10, 2025 (GLOBE NEWSWIRE) — <\/strong>
\n EUDA Health Holdings Limited\u00a0<\/i>(NASDAQ: EUDA) (\u201cEUDA\u201d or the \u201cCompany\u201d), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte. Ltd. (\u201cEUDA Health\u201d), has signed a Letter of Intent (the \u201cLOI\u201d) to potentially acquire GO POSB Organoids Pte Ltd (\u201cGO POSB\u201d), a biotechnology company formed in Singapore. <\/p>\n

GO POSB has developed a proprietary induced pluripotent stem cell (iPSC) platform<\/b> that reprograms human blood cells into clinical-grade, therapeutics-ready stem cells. These iPSCs can differentiate into nearly any cell type in the human body, unlocking applications in drug discovery, disease modelling, regenerative medicine, and future cell-based therapies. Importantly, iPSCs provide pluripotency without the ethical concerns linked to embryonic stem cells, making them one of the most promising frontiers in biotechnology.<\/p>\n

\n Strategic Expansion into iPSC Solutions<\/b>\n <\/p>\n

Under the LOI, EUDA and GO POSB are exploring the establishment of a state-of-the-art iPSC laboratory and cultivation facility in Shenzhen, China.<\/b> The facility would serve as a hub to store, expand, and distribute iPSC solutions to hospitals, clinics, and research centers across China, subject to regulatory approvals. EUDA will provide funding for the build-out while the two companies collaborate with Singapore\u2019s Agency for Science, Technology and Research (A*STAR) to advance iPSC research, conduct clinical trials, and accelerate regulatory pathways for therapeutic applications.<\/p>\n

The collaboration will position EUDA to supply B2B iPSC solutions<\/b> to the downstream healthcare ecosystem, including hospitals, regenerative clinics, and biotech developers. Beyond core therapeutic applications, the platform also opens future opportunities for off-the-shelf iPSC-derived product lines<\/b> tailored for Asia\u2019s wellness and aesthetics markets, such as iPSC-based hair rejuvenation and facial treatments<\/b>. These initiatives are designed to directly complement EUDA\u2019s growing portfolio of stem cell treatments and supplements, reinforcing the Company\u2019s integrated approach to longevity and regenerative health.<\/p>\n

\n About EUDA Health Holdings Limited<\/b>\n <\/p>\n

EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.<\/p>\n

\n Forward<\/b>\u00a0Looking<\/b>\u00a0Statements<\/b><\/p>\n

This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words \u201cestimates,\u201d \u201cprojected,\u201d \u201cexpects,\u201d \u201cenvisions,\u201d \u201canticipates,\u201d \u201cforecasts,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cbelieves,\u201d \u201cseeks,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cfuture,\u201d \u201cpropose\u201d and variations of these words or similar expressions (or the negative versions of such words or expressions).These forward-looking statements are not guarantees of future performance, conditions or results, and involve a\u00a0number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA\u2019s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. These forward-looking statements are based on information from EUDA and Go POSB, as well as other sources that we believe are reliable. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n

Contact:<\/p>\n

Christensen Advisory<\/p>\n

Linda Bergkamp<\/p>\n

Phone: +1-480-614-3004 <\/p>\n

E-mail: linda.bergkamp@christensencomms.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SINGAPORE, Sept. 10, 2025 (GLOBE NEWSWIRE) — EUDA Health Holdings Limited\u00a0(NASDAQ: EUDA) (\u201cEUDA\u201d or the \u201cCompany\u201d), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte. Ltd. (\u201cEUDA Health\u201d), has signed a Letter of Intent (the \u201cLOI\u201d) to potentially acquire GO POSB Organoids Pte Ltd (\u201cGO POSB\u201d), a biotechnology company formed in Singapore. GO POSB has developed a proprietary induced pluripotent stem cell (iPSC) platform that reprograms human blood cells into clinical-grade, therapeutics-ready stem cells. These iPSCs can differentiate into nearly any cell type in the human body, unlocking applications in drug discovery, disease modelling, regenerative medicine, and future cell-based therapies. Importantly, iPSCs provide pluripotency without the ethical … <\/p>\n

Continue reading “EUDA Signs Letter of Intent to Potentially Acquire GO POSB”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-885145","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEUDA Signs Letter of Intent to Potentially Acquire GO POSB - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EUDA Signs Letter of Intent to Potentially Acquire GO POSB - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SINGAPORE, Sept. 10, 2025 (GLOBE NEWSWIRE) — EUDA Health Holdings Limited\u00a0(NASDAQ: EUDA) (\u201cEUDA\u201d or the \u201cCompany\u201d), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte. Ltd. (\u201cEUDA Health\u201d), has signed a Letter of Intent (the \u201cLOI\u201d) to potentially acquire GO POSB Organoids Pte Ltd (\u201cGO POSB\u201d), a biotechnology company formed in Singapore. GO POSB has developed a proprietary induced pluripotent stem cell (iPSC) platform that reprograms human blood cells into clinical-grade, therapeutics-ready stem cells. These iPSCs can differentiate into nearly any cell type in the human body, unlocking applications in drug discovery, disease modelling, regenerative medicine, and future cell-based therapies. Importantly, iPSCs provide pluripotency without the ethical … Continue reading "EUDA Signs Letter of Intent to Potentially Acquire GO POSB"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-10T13:33:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNjczMCM3MTQwMzU4IzUwMDEyNDQzOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"EUDA Signs Letter of Intent to Potentially Acquire GO POSB\",\"datePublished\":\"2025-09-10T13:33:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\\\/\"},\"wordCount\":624,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyNjczMCM3MTQwMzU4IzUwMDEyNDQzOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\\\/\",\"name\":\"EUDA Signs Letter of Intent to Potentially Acquire GO POSB - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyNjczMCM3MTQwMzU4IzUwMDEyNDQzOQ==\",\"datePublished\":\"2025-09-10T13:33:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyNjczMCM3MTQwMzU4IzUwMDEyNDQzOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyNjczMCM3MTQwMzU4IzUwMDEyNDQzOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EUDA Signs Letter of Intent to Potentially Acquire GO POSB\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EUDA Signs Letter of Intent to Potentially Acquire GO POSB - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\/","og_locale":"en_US","og_type":"article","og_title":"EUDA Signs Letter of Intent to Potentially Acquire GO POSB - Market Newsdesk","og_description":"SINGAPORE, Sept. 10, 2025 (GLOBE NEWSWIRE) — EUDA Health Holdings Limited\u00a0(NASDAQ: EUDA) (\u201cEUDA\u201d or the \u201cCompany\u201d), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte. Ltd. (\u201cEUDA Health\u201d), has signed a Letter of Intent (the \u201cLOI\u201d) to potentially acquire GO POSB Organoids Pte Ltd (\u201cGO POSB\u201d), a biotechnology company formed in Singapore. GO POSB has developed a proprietary induced pluripotent stem cell (iPSC) platform that reprograms human blood cells into clinical-grade, therapeutics-ready stem cells. These iPSCs can differentiate into nearly any cell type in the human body, unlocking applications in drug discovery, disease modelling, regenerative medicine, and future cell-based therapies. Importantly, iPSCs provide pluripotency without the ethical … Continue reading \"EUDA Signs Letter of Intent to Potentially Acquire GO POSB\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-10T13:33:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNjczMCM3MTQwMzU4IzUwMDEyNDQzOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"EUDA Signs Letter of Intent to Potentially Acquire GO POSB","datePublished":"2025-09-10T13:33:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\/"},"wordCount":624,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNjczMCM3MTQwMzU4IzUwMDEyNDQzOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\/","name":"EUDA Signs Letter of Intent to Potentially Acquire GO POSB - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNjczMCM3MTQwMzU4IzUwMDEyNDQzOQ==","datePublished":"2025-09-10T13:33:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNjczMCM3MTQwMzU4IzUwMDEyNDQzOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyNjczMCM3MTQwMzU4IzUwMDEyNDQzOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-signs-letter-of-intent-to-potentially-acquire-go-posb\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"EUDA Signs Letter of Intent to Potentially Acquire GO POSB"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/885145","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=885145"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/885145\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=885145"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=885145"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=885145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}